Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury

Mahidol University

Status and phase: Completed; Phase 3; Phase 2

Conditions: AKI; Cirrhosis, Liver

Treatments: Drug: Dextran 40

Study type: Interventional

Funder types: Other

Identifiers

NCT03070353

ID 11-57-21

Details and patient eligibility

About

A pilot study of Dextran-40 infusion in patients with decompensated cirrhosis presenting with AKI

Full description

A pilot study of Dextran-40 infusion in decompensated cirrhotic patients complicating with AKI. Dextran-40® was administered at 1 g/kg/day for two days. AKI reversal was defined when serum creatinine was < 1.5 mg/dL. Albumin infusion was given if AKI reversal did not occur.

Enrollment: 10 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Decompensated cirrhosis with acute kidney injury
• Ager over 18 years old

Exclusion criteria

• Having chronic kidney disease, severe heart or lung disease, severe sepsis
• Pregnant
• Receiving nephrotoxic agents
• Having history of allergic to Dextran

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Dextran 40

Experimental group

Description:

Dextran 40 infusion

Treatment:

Drug: Dextran 40